HLB Co., Ltd. (KOSDAQ:028300)
37,750
+100 (0.26%)
Aug 29, 2025, 3:30 PM KST
HLB Co., Ltd. Revenue
HLB Co., Ltd. had revenue of 15.73B KRW in the quarter ending June 30, 2025, with 6.34% growth. This brings the company's revenue in the last twelve months to 75.57B, up 69.07% year-over-year. In the year 2024, HLB Co., Ltd. had annual revenue of 68.13B with 58.80% growth.
Revenue (ttm)
75.57B
Revenue Growth
+69.07%
P/S Ratio
65.53
Revenue / Employee
481.36M
Employees
157
Market Cap
4,952.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
Dec 31, 2020 | 56.18B | 17.76B | 46.22% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
PharmaResearch | 392.31B |
Peptron | 4.30B |
LigaChem Biosciences | 146.42B |